🔗 Share this article

A high-ranking health figure was taken off of involvement regarding a key research project concerning gender-affirming medication subsequent to claims regarding preconceived views emerged.

Reported Intervention Led to Trial Halt

As reported by media coverage, Professor Jacob George, a chief medical director for the medicines regulator, voiced issues that resulted in the suspension of the government-funded Pathways trial in early 2024.

The agency announced recently that George was recusing himself from participation in the trial once gender-critical social media remarks made in the past emerged.

Content Regarding the Social Media Comments

In a comment, he described author J.K. Rowling being a “treasure of our time.” Elsewhere, the professor stated how “the denial to accept fundamental biological fact was troubling” regarding debates about an Olympic boxer’s sex.

The regulator said that even though the comments were posted prior to his appointment, the official was taken off from oversight in the study as an preventative measure.

Details of the Halted Clinical Study

This research project, that was designed to assess the effect of hormone suppressants for children uncertain about their gender identity, was scheduled to start recruiting volunteers in January.

But, it was paused in the following month when its agency expressed worries regarding the safety of young participants participating.

• The youngest volunteers were anticipated to start at ten to eleven for assigned female at birth and eleven to twelve for assigned male at birth.
• The research organizers noted previously how the rigorous selection procedure suggested participants would almost certainly be of a higher age.
• However, the agency have since recommended the minimum age requirement must be fourteen because of the uncertain potential” of lasting physical side effects.”

This study was designed to recruit a projected 226 youths during the following several years.

Background and a Independent Report

This study was announced subsequent to an urging from an independent inquiry on youth gender care, that found that the quality of the research purporting to prove the advantages of such medication in youngsters experiencing gender dysphoria were low-quality.”

Doctor Hilary Cass, who led that report, once stated the findings “uncovered an extremely poor evidence base” supporting the benefits of puberty blockers.

Dr. Cass noted, since there exist medical professionals, young people as well as parents that believe strongly of the helpful results, a trial was the only way forward to clarify this.”

Medical Criticism Regarding the Action

Doctor Max Davie, an expert in adolescent medicine, stated there was no convincing scientific reason to suspend the study.

“The social media posts from Prof George provide a clear indication into his personal views regarding gender identity,” he said. “He is quite at liberty to hold whatever views about this subject he wishes, however what is improper is let these opinions to affect the performance of his official role.”

He concluded: “It must be understood, there exists no persuasive medical basis to stop the Pathways trial. Although Prof George’s individual beliefs is not the sole possible explanation of the regulator’s abrupt reversal, they are the single factor where we possess proof.”

Agency Response Regarding Future Actions

A regulatory spokesperson stated: “With all clinical trials, our foremost duty is the safety and welfare of the volunteers. As part of this duty, detailed studies are kept continuously under review while the agency maintains an active discussion alongside study funders.”

“We have world-class medical, scientific and regulatory professionals who function in a collaborative team to make scientifically sound judgments regarding clinical trials. These experts will continue to engage alongside the organizers to work through the subsequent actions constructively.”

“Subsequent to the finding of social media posts posted prior to his appointment, Prof Jacob George was recused of any additional oversight on this clinical trial as a precaution.”